These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23565676)

  • 21. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Kümler I; Palshof JA; Andersson M
    Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
    Lehr HA; Schaefer SC; Delaloye JF
    Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tumor resistance to HER2 inhibitors: the drug sedimentation concept].
    Campone M; Frenel JS; André F; Bachelot T; Juin P
    Bull Cancer; 2012 Jun; 99(6):665-72. PubMed ID: 22614782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer.
    Nixon NA; Hannouf MB; Verma S
    Eur J Cancer; 2018 Jan; 89():72-81. PubMed ID: 29241083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormone receptor status might be a determinant for HER2 loss after HER2-targeted treatment in HER2 positive breast cancer patients.
    Altundag K
    J BUON; 2019; 24(5):2206. PubMed ID: 31786897
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.
    Yu Q; Zhu Z; Liu Y; Zhang J; Li K
    PLoS One; 2015; 10(5):e0127404. PubMed ID: 25993646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?
    Wu VS; Kanaya N; Lo C; Mortimer J; Chen S
    J Steroid Biochem Mol Biol; 2015 Sep; 153():45-53. PubMed ID: 25998416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
    De Mattos-Arruda L; Cortes J
    Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to Anti-HER2 Therapies in Breast Cancer.
    Rimawi MF; De Angelis C; Schiff R
    Am Soc Clin Oncol Educ Book; 2015; ():e157-64. PubMed ID: 25993167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies.
    Florido R; Smith KL; Cuomo KK; Russell SD
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939718
    [No Abstract]   [Full Text] [Related]  

  • 33. Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance.
    Chung A; Cui X; Audeh W; Giuliano A
    Clin Breast Cancer; 2013 Aug; 13(4):223-32. PubMed ID: 23829888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
    Huang Y; Fu P; Fan W
    Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives.
    Soto-Perez-De-Celis E; Loh KP; Baldini C; Battisti NML; Chavarri-Guerra Y; De Glas NA; Hsu T; Hurria A
    Expert Opin Investig Drugs; 2018 Oct; 27(10):787-801. PubMed ID: 30196727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
    Siddique AB; Ebrahim HY; Akl MR; Ayoub NM; Goda AA; Mohyeldin MM; Nagumalli SK; Hananeh WM; Liu YY; Meyer SA; El Sayed KA
    Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
    Leech AO; Vellanki SH; Rutherford EJ; Keogh A; Jahns H; Hudson L; O'Donovan N; Sabri S; Abdulkarim B; Sheehan KM; Kay EW; Young LS; Hill ADK; Smith YE; Hopkins AM
    Breast Cancer Res; 2018 Nov; 20(1):140. PubMed ID: 30458861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
    Kelly CM; Buzdar AU
    Drugs; 2013 May; 73(6):505-15. PubMed ID: 23605692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
    Fernández-Nogueira P; Mancino M; Fuster G; López-Plana A; Jauregui P; Almendro V; Enreig E; Menéndez S; Rojo F; Noguera-Castells A; Bill A; Gaither LA; Serrano L; Recalde-Percaz L; Moragas N; Alonso R; Ametller E; Rovira A; Lluch A; Albanell J; Gascon P; Bragado P
    Clin Cancer Res; 2020 Mar; 26(6):1432-1448. PubMed ID: 31699826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.